House Republicans are currently investigating a controversial DEA tactic that has drawn scrutiny for its potential role in the ongoing fentanyl crisis. The practice, colloquially known as 'letting drugs walk,' involves law enforcement allowing illicit substances to move through distribution networks in an attempt to track and apprehend higher-level traffickers. Critics of the tactic argue that this method carries significant risks, as it may inadvertently allow dangerous narcotics to reach the streets rather than being intercepted.

The investigation seeks to determine the extent to which this strategy was utilized during the Trump administration and whether it remains an active component of current federal drug enforcement operations. While the DEA has historically defended such operations as necessary tools for dismantling large-scale criminal organizations, lawmakers are now questioning the oversight and efficacy of these programs in light of the record-high fentanyl overdose rates. The inquiry aims to establish a clearer timeline of when these tactics were employed and what internal protocols were in place to mitigate the risk of drugs disappearing into the illicit market. As the investigation proceeds, the central point of debate remains whether the potential intelligence gains from tracking drug shipments outweigh the public safety hazards posed by allowing controlled substances to circulate unchecked.